Dermatopontin Antibody [Alexa Fluor™ Plus 594]

• Reactivity: Hu
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor Plus 594

Dermatopontin Antibody [Alexa Fluor™ Plus 594] Summary

• Specificity: Detects human Dermatopontin in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant mouse Dermatopontin is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Dermatopontin Antibody [Alexa Fluor™ Plus 594]

• Dermatopontin
• DPT
• Eq1
• TRAMP
• Tyrosine-rich acidic matrix protein

Background

Dermatopontin, also known as TRAMP (tyrosine rich acidic matrix protein), is a widely expressed noncollagenous protein component of the extracellular matrix (1, 2). Mature human Dermatopontin shares 96%, 92%, and 92% amino acid sequence identity with bovine, mouse, and rat Dermatopontin, respectively. It is a 22 kDa molecule that is tyrosine sulfated but not glycosylated (3, 4). Dermatopontin contains three disulfide bonded loop structures that enclose conserved hexapeptide motifs (5). It accelerates collagen fibril formation in vitro, and Dermatopontin deficient mice exhibit altered collagen matrix deposition and organization (6 - 8). Dermatopontin is downregulated in fibrotic growths such as leiomyoma and scar tissue (9, 10). It binds both TGF-beta and the proteoglycan decorin, interactions that can increase the bioavailability of TGF-beta (11, 12). Dermatopontin promotes bone mineralization under the control of the vitamin D receptor and inhibits BMP-2 effects on osteoblast precursors (13, 14).

1. Okamoto, O. and S. Fujiwara (2006) Connect. Tissue Res. 47:177.
2. Superti-Furga, A. et al. (1993) Genomics 17:463.
3. Forbes, E.G. et al. (1994) FEBS Lett. 351:433.
4. Cronshaw, A.D. et al. (1993) Matrix 13:255.
5. Neame, P.J. et al. (1989) J. Biol. Chem. 264:5474.
6. MacBeath, J.R.E. et al. (1993) J. Biol. Chem. 268:19826.
7. Takeda, U. et al. (2002) J. Invest. Dermatol. 119:678.
8. Cooper, L.J. et al. (2006) Invest. Opthalmol. Vis. Sci. 47:3303.
9. Catherino, W.H. et al. (2004) Genes Chromosomes Cancer 40:204.
10. Kuroda, K. et al. (1999) J. Invest. Dermatol. 112:706.
11. Okamoto, O. et al. (1996) J. Biochem. 119:106.
12. Okamoto, O. et al. (1999) Biochem. J. 337:537.
13. Pochampally, R.R. et al. (2007) J. Bone Miner. Res. 22:1338.
14. Behnam, K. et al. (2006) Connect. Tissue Res. 47:271.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.